Vitamin D Therapy Market Report 2025

The vitamin d therapy market size has grown rapidly in recent years. It will grow from $2.92 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing awareness of vitamin D deficiency, growing incidence of bone disorders, aging population and osteoporosis prevalence, scientific research highlighting benefits, increase in lifestyle-related diseases, medical recommendations for supplementation.

The vitamin d therapy market size is expected to see rapid growth in the next few years. It will grow to $5.44 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to continued awareness and education, rising geriatric population, integration of vitamin D in chronic disease management, technological advances in formulations, global health initiatives, increased focus on personalized nutrition. Major trends in the forecast period include expanding applications beyond bone health, government initiatives for supplementation, innovations in formulations and delivery methods, focus on clinical research and evidence-based practices, global market expansion.

The rising incidence of malnutrition cases is anticipated to drive the growth of the vitamin D therapy market in the future. Malnutrition encompasses deficiencies or excesses in nutrient intake, imbalances of essential nutrients, or impaired nutrient utilization. Vitamin D deficiency is notably common among malnourished inpatients and is negatively correlated with long-term mortality, especially when patients are not receiving vitamin D treatment. Consequently, the growing prevalence of malnutrition cases is increasing the demand for vitamin D therapy. For example, in March 2024, the World Health Organization, a Switzerland-based agency dedicated to promoting health, ensuring global safety, and assisting vulnerable populations, reported that in 2022, around 390 million adults aged 18 years and older worldwide were underweight, while 2.5 billion were overweight, including 890 million living with obesity. Among children and adolescents aged 5 to 19 years, 390 million were overweight, with 160 million living with obesity, and another 190 million were classified as thin. An estimated 149 million children under the age of 5 were suffering from stunting, while 37 million were living with overweight or obesity. Nearly half of all deaths among children under 5 years old are linked to undernutrition. Therefore, the increasing prevalence of malnutrition cases is driving the growth of the vitamin D therapy market.

The rising prevalence of chronic diseases is expected to boost the demand for the vitamin D therapy market in the future. Chronic diseases are persistent, progress over time, and typically worsen if lifestyle changes are not made. Examples of chronic diseases include Alzheimer's disease, rheumatoid arthritis, Parkinson's disease, and cancer. Vitamin D therapy is essential in managing chronic diseases by addressing related complications and supporting overall health. Numerous studies indicate a connection between vitamin D deficiency and an elevated risk of chronic conditions such as cardiovascular diseases, diabetes, and certain cancers. Maintaining adequate vitamin D levels is vital for immune system regulation, cardiovascular health, and metabolic function. Individuals with chronic diseases often show lower vitamin D levels, and supplementation is considered a valuable adjunct in their management. For instance, in May 2024, the National Cancer Institute (NCI), a U.S.-based federal agency focused on cancer research and training, reported that in 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 people expected to die from cancer. Prostate, lung, and colorectal cancers are projected to account for about 48% of all cancers diagnosed in men in 2024. For women, the three most common cancers will be breast, lung, and colorectal, collectively representing an estimated 51% of all new cancer diagnoses in women in 2024. The number of cancer survivors is anticipated to rise to 22.5 million by 2032. Therefore, the increasing prevalence of chronic diseases is driving the growth of the vitamin D therapy market.

Product innovations are a significant trend gaining traction in the vitamin D therapy market. Major companies in this sector are launching innovative products to maintain their competitive edge. For example, in February 2024, Cadila Pharmaceuticals Pvt Ltd., a multinational pharmaceutical company based in India, introduced its first aqueous formulation, Cadila Pharmaceuticals’ Aqueous Cholecalciferol Injection, which sets a new standard in treating vitamin D deficiency. This unique solution provides rapid correction of vitamin D deficiency in a short period. This groundbreaking innovation showcases superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to traditional oil-based cholecalciferol preparations available on the market.

Major companies operating in the vitamin D therapy market are forming partnerships to enhance their market position. A strategic business partnership is a structured alliance between two or more commercial entities, usually established through one or more business agreements or contracts. For example, in July 2024, Catalyst Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, entered into a License, Supply, and Commercialization Agreement with Kye Pharmaceuticals Inc., a Canada-based pharmaceutical company, granting Kye the exclusive Canadian commercial rights to AGAMREE (vamorolone). Vamorolone is utilized in the treatment of Duchenne muscular dystrophy (DMD), which is related to vitamin deficiency.

In June 2022, Nestle Health Science, a Switzerland-based nutritional science company, made an undisclosed acquisition of The Better Health Company (TBHC). This strategic acquisition is anticipated to synergize with Nestle's global portfolio, specifically enhancing its active lifestyle and health & wellness nutrition brands. Additionally, it positions Nestle Health Science to expedite growth by leveraging TBHC's manufacturing facility in Auckland, facilitating the swift introduction of new products into local markets. The Better Health Company, based in the US, brings its expertise in natural health products to complement Nestle's strategic objectives, signaling a strategic move towards bolstering their market presence and product offerings in the health and wellness domain.

Major companies operating in the vitamin d therapy market are Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Pfizer Inc., Merck & Co Inc., Torrent Pharmaceuticals Ltd., Novartis International AG, Alkem Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Biotics Research Corporation, Solvay Pharma India Pvt. Ltd., Forgo Pharmaceuticals Ltd., Mankind Pharmaceuticals Pvt. Ltd., Cipla Ltd., Ortho Molecular Products, Zhejiang Garden Biochemical High-tech Co. Ltd., Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Ltd., Mylan N.V., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Biocare Medical LLC, Mitsubishi Chemical Group, Zydus Cadila, DSM Nutritional Products AG, BASF SE, Fermenta Biotech Ltd., Taizhou Hisound Pharmaceutical Co. Ltd.

North America was the largest region in the vitamin D therapy market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vitamin d therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vitamin d therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vitamin D therapy involves the use of supplements commonly prescribed to treat and prevent vitamin D deficiency. These supplements contribute to the regulation of calcium and phosphorus levels in the body and play a crucial role in maintaining proper bone structure. Vitamin D therapy is also considered in cases of depression where a vitamin D deficiency is identified.

The administration methods for vitamin D therapy include oral and parenteral routes. Oral administration involves ingestion through the mouth. Various purchasing options are available, including over-the-counter (OTC) drugs and prescription drugs. These supplements cater to diverse age groups, including children, adults, and senior citizens, addressing conditions such as osteoporosis, rickets, skin diseases, muscle weakness, and autoimmune disorders.

The vitamin D therapy market research report is one of a series of new reports that provides vitamin D therapy market statistics, including vitamin D therapy industry global market size, regional shares, competitors with vitamin D therapy market share, detailed vitamin D therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the vitamin D therapy industry. This vitamin D therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vitamin D therapy market consists of sales of plain vitamin D therapy and active vitamin D analog (or D-hormone) therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.